Menopausal syndromes includes somatic symptom, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. Hormone therapy (HT) is widely used for controlling menopausal symptoms. Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine estrogens \& MPA. However, only a few literatures mentioned about the therapeutic effect of tibolone, but lack of comparison research about their therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. The knowledge of the above therapeutic effects should be important for choosing a suitable medication. Therefore, the aim of this study is to assess the therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms between tibolone and E2V/MPA.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
125
Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan
Menopausal symptoms
To clarify any difference of reduction in menopausal symptom scores between these two groups
Time frame: 12 weeks
sexual function
To clarify any difference of improvements of sexual function scores between these two groups
Time frame: 12 weeks
lower urinary tract symptoms
To clarify any difference of improvements of lower urinary tract symptoms scores between these two groups
Time frame: 12 weeks
psychosomatic symptoms
To clarify any difference of improvements of psychosomatic symptoms scores between these two groups
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.